Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs.
Gilabert M, Vaccaro MI, Fernandez-Zapico ME, Calvo EL, Turrini O, Secq V, Garcia S, Moutardier V, Lomberk G, Dusetti N, Urrutia R, Iovanna JL.SourceCancer Research Center of Marseille, INSERM U624, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University, Marseille, France; CNRS UMR 7258, Marseille, France.
Journal of cellular physiology.J Cell Physiol.2013 Sep;228(9):1834-43. doi: 10.1002/jcp.24343.
We hypothesized that inhibiting molecules that mediate the adaptation response to cellular stress can antagonize the resistance of pancreatic cancer cells to chemotherapeutic drugs. Toward this end, here, we investigated how VMP1, a stress-induced autophagy-associated protein, modulate stress respon
Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
Vincent M, Bessard A, Cochonneau D, Teppaz G, Solé V, Maillasson M, Birklé S, Garrigue-Antar L, Quéméner A, Jacques Y.SourceCentre de Recherche en Cancérologie Nantes-Angers, Inserm, U892, CNRS, U6299, équipe Cytokines et Récepteurs en Immuno-Hémato-Cancérologie, Université de Nantes, Nantes, France.
International journal of cancer. Journal international du cancer.Int J Cancer.2013 Aug 1;133(3):757-65. doi: 10.1002/ijc.28059. Epub 2013 Feb 25.
Immunocytokines (ICKs) targeting cytokines to the tumor environment using antibodies directed against a tumor-associated antigen often have a higher therapeutic index than the corresponding unconjugated cytokines. Various ICKs displaying significant antitumoral effects in several murine tumor models
TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells.
Jähnisch H, Wehner R, Tunger A, Kunze A, Oehrl S, Schäkel K, Rohayem J, Bornhäuser M, Tonn T, Bachmann M, Schmitz M.SourceInstitute of Immunology, Medical Faculty, Technical University of Dresden, Dresden, Germany.
Cancer letters.Cancer Lett.2013 Jul 10;335(1):119-27. doi: 10.1016/j.canlet.2013.02.003. Epub 2013 Feb 9.
Imiquimod and resiquimod represent Toll-like receptor (TLR) 7 and 8 agonists, which emerged as attractive candidates for tumor therapy. To elucidate immune cells, which mainly contribute to TLR7/8-mediated antitumoral activity, we investigated the impact of imiquimod and resiquimod on native human 6